DOC vs RYN
Healthpeak Properties vs Rayonier — AI-powered side-by-side comparison
DOC
Healthpeak Properties
64
Buy
VS
| Metric | DOC | RYN |
|---|
| AI Score |
64
|
70
|
| Price |
$20.50
|
$21.46
|
| P/E Ratio |
58.60×
|
43.75×
|
| ROE |
1.0%
|
21.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
2.5%
|
17.9%
|
| Debt / Equity |
1.32×
|
0.36×
|
| Dividend Yield |
5.9%
|
11.5%
|
| RSI (14) |
31.1
|
49.8
|
| Beta |
0.991
|
0.904
|
| Expected Upside |
+1.6%
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for DOC versus RYN.
RYN leads by 6 points.
RYN scores 70/100 (Buy) versus DOC at 64/100 (Buy).
DOC Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Price trading below the lower Bollinger Band -- stretched to the downside — Technical
RYN Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical